Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $60.6 million.

  • Gyre Therapeutics' Non-Current Assets fell 13.66% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year decrease of 13.66%. This contributed to the annual value of $60.6 million for FY2024, which is 2.19% up from last year.
  • As of FY2024, Gyre Therapeutics' Non-Current Assets stood at $60.6 million, which was up 2.19% from $59.3 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Non-Current Assets registered a high of $60.6 million during FY2024, and its lowest value of $4.2 million during FY2021.
  • In the last 3 years, Gyre Therapeutics' Non-Current Assets had a median value of $59.3 million in 2023 and averaged $51.7 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Non-Current Assets fell by 21.55% in 2021, and later soared by 738.51% in 2022.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Non-Current Assets stood at $5.3 million in 2020, then fell by 21.55% to $4.2 million in 2021, then soared by 738.51% to $35.1 million in 2022, then spiked by 69.00% to $59.3 million in 2023, then rose by 2.19% to $60.6 million in 2024.